Repligen Corporation $RGEN Position Raised by TimesSquare Capital Management LLC

TimesSquare Capital Management LLC raised its stake in Repligen Corporation (NASDAQ:RGEN) by 20.3% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 435,687 shares of the biotechnology company’s stock after buying an additional 73,558 shares during the quarter. TimesSquare Capital Management LLC’s holdings in Repligen were worth $71,392,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently added to or reduced their stakes in RGEN. AQR Capital Management LLC bought a new stake in Repligen in the first quarter valued at $262,000. Jones Financial Companies Lllp lifted its stake in Repligen by 3,850.6% in the first quarter. Jones Financial Companies Lllp now owns 6,400 shares of the biotechnology company’s stock valued at $814,000 after buying an additional 6,238 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in Repligen by 16.8% in the first quarter. Goldman Sachs Group Inc. now owns 141,994 shares of the biotechnology company’s stock valued at $18,067,000 after buying an additional 20,375 shares during the last quarter. Bank of Nova Scotia lifted its stake in Repligen by 88.0% in the second quarter. Bank of Nova Scotia now owns 31,747 shares of the biotechnology company’s stock valued at $3,951,000 after buying an additional 14,860 shares during the last quarter. Finally, Daiwa Securities Group Inc. lifted its stake in Repligen by 29.7% in the second quarter. Daiwa Securities Group Inc. now owns 31,194 shares of the biotechnology company’s stock valued at $3,880,000 after buying an additional 7,148 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. UBS Group cut their target price on Repligen from $200.00 to $195.00 and set a “buy” rating on the stock in a research note on Wednesday, February 25th. Wall Street Zen cut Repligen from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Jefferies Financial Group reiterated a “hold” rating and issued a $142.00 target price on shares of Repligen in a research note on Tuesday, May 5th. KeyCorp restated an “overweight” rating on shares of Repligen in a research note on Wednesday, February 25th. Finally, Rothschild & Co Redburn set a $160.00 price objective on shares of Repligen and gave the company a “buy” rating in a research note on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $166.15.

Repligen Price Performance

Shares of NASDAQ RGEN opened at $104.20 on Tuesday. Repligen Corporation has a fifty-two week low of $100.99 and a fifty-two week high of $175.77. The firm’s 50-day simple moving average is $118.54 and its 200 day simple moving average is $141.71. The company has a quick ratio of 7.78, a current ratio of 9.20 and a debt-to-equity ratio of 0.26. The stock has a market cap of $5.88 billion, a P/E ratio of 115.78, a P/E/G ratio of 1.98 and a beta of 1.09.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.10. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The business had revenue of $194.26 million for the quarter, compared to analysts’ expectations of $192.05 million. During the same period in the previous year, the business earned $0.39 earnings per share. The company’s revenue was up 14.8% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. Equities analysts expect that Repligen Corporation will post 1.99 EPS for the current year.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.